AUS
NZ
UK
CA
USA
IND
Highlights
- Kane Biotech continues to commercialize its FDA-cleared and Health Canada-approved revyve® wound care products.
- The revyve® platform targets biofilms, a major contributor to antibiotic resistance in wounds.
- The Company is focusing on expanding commercialization across Canada and the United States.
- Kane Biotech has strengthened its U.S. strategy through a distribution partnership and sales representative agreements.
Wound infections remain one of the biggest challenges in healthcare, particularly when biofilms make bacteria significantly more resistant to treatment. As the need for more effective wound care solutions continues to grow, Kane Biotech Inc. (TSX-V:KNE) is positioning its revyve® platform to address this critical issue. Backed by regulatory clearances in North America and an expanding commercialization strategy, the Company is focusing on bringing its biofilm-targeting wound care products to a broader healthcare market while advancing its transition into a dedicated human wound care business.
Targeting Biofilms in Wound Care
Biofilms are a major challenge in wound treatment because they make bacteria much harder to eliminate. Based on scientific evidence, bacteria protected by biofilms can become up to 1,000 times more resistant to antibiotics, disinfectants, antimicrobial agents, and the body's natural immune response. This can delay healing and make wound management more difficult.
Kane Biotech developed the revyve® platform to help address both biofilms and wound bacteria. Its product range includes revyve® Antimicrobial Wound Gel, revyve® Antimicrobial Wound Gel Spray, and revyve® Antimicrobial Skin and Wound Cleanser. All three products have received U.S. FDA 510(k) clearance, while the wound gel and wound gel spray are also approved by Health Canada.
Triple-Action Wound Care Solution
The revyve® Antimicrobial Wound Gel combines several ingredients designed to support wound care.
Its formulation features Kane Biotech's patented coactiv+® technology, which includes EDTA and citric acid, together with PHMB to provide antimicrobial and antibiofilm activity.
The gel also contains a non-ionic pluronic surfactant with thermo-gelling properties that aids in wound cleansing while maintaining an optimal moist wound environment. This also helps the product spread easily, stay in place after application, and rinse off with minimal effort. According to the Company, the hydrogel is designed to be an accessible option for different healthcare settings.
Strengthening U.S. Market Reach
In March 2026, Kane Biotech expanded its U.S. commercialization strategy through new partnerships. The company entered into a distribution agreement with Marathon Medical Corporation, a federally verified Service Disabled Veteran Owned Small Business (SDVOSB) and a nationwide medical supply distributor.
The partnership is expected to support access to federal healthcare channels, including the U.S. Veterans Affairs (VA), Department of Defense (DOD), and Indian Health Services (IHS).
Alongside the distribution agreement, Kane Biotech also appointed multiple independent U.S.-based sales representatives to support the wider commercialization of its advanced wound care portfolio, including revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray.
Kane Biotech is continuing to expand the commercial reach of its revyve® wound care platform through regulatory approvals and strategic partnerships. With a growing distribution network and a focus on biofilm-targeting wound care products, the company is working to increase the availability of its portfolio across healthcare markets in Canada and the United States, as well as outside North America.
Shares of KNE traded at CAD 0.025 on July 03, 2026 .
